文献速递心力衰竭与心肌病

GLP-1受体激动剂与心力衰竭:孟德尔随机化提示新获益

GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.
PubMed 文献 · Eur Heart J · 2026-01-01

本研究采用两样本顺式孟德尔随机化,以糖化血红蛋白降低作为GLP-1R激活的替代标志,评估其对心力衰竭风险的影响。结果显示,GLP-1R激活与心衰风险降低相关,且该效应主要由体重指数降低介导,但未完全被体重指数或2型糖尿病解释。

要点

  • 遗传学模拟的GLP-1R激活与心衰风险降低约50%相关。
  • 体重指数降低是主要介导因素,而非血糖控制。
  • 校正体重指数和2型糖尿病后仍存在残余保护效应。

核心结论

  • GLP-1受体激动剂相关的心衰风险降低主要由体重指数降低介导,而非血糖控制,但两者均不能完全解释该效应。
  • 校正体重指数和2型糖尿病后的残余效应提示存在直接的心脏保护作用。

研究设计与样本

  • 采用两样本顺式孟德尔随机化评估GLP-1R激活对心衰风险的因果效应,以糖化血红蛋白降低作为替代生物标志物。
  • 主要分析使用逆方差加权法和MR-RAPS法。

主要发现

  • 遗传学模拟的GLP-1R激活与心衰风险降低相关:IVW法OR为.502(95%CI .339–.743),MR-RAPS法OR为.492(95%CI .320–.756)。
  • 孟德尔随机化贝叶斯模型平均确定体重指数(边际纳入概率67.2%)和2型糖尿病(45.0%)为主要介导因素。
  • 多变量顺式MR中,校正体重指数后,GLP-1R位点遗传预测的糖化血红蛋白水平仍与心衰风险显著相关(OR 1.663,95%CI 1.087–2.544,99%方差阈值)。
  • 网络顺式MR证实校正体重指数后保护效应持续:IVW法OR为.587(95%CI .394–.877),MR-RAPS法OR为.577(95%CI .375–.887)。
  • 网络顺式MR证实校正2型糖尿病后保护效应持续:IVW法OR为.508(95%CI .343–.754),MR-RAPS法OR为.499(95%CI .327–.762)。

关键数值与推荐

  • GLP-1R激活与心衰风险:IVW法OR .502(95%CI .339–.743),MR-RAPS法OR .492(95%CI .320–.756)。
  • 体重指数边际纳入概率67.2%,2型糖尿病边际纳入概率45.0%。
  • 校正体重指数后糖化血红蛋白与心衰风险:OR 1.663(95%CI 1.087–2.544)。
  • 校正体重指数后GLP-1R激活与心衰风险:IVW法OR .587(95%CI .394–.877),MR-RAPS法OR .577(95%CI .375–.887)。
  • 校正2型糖尿病后GLP-1R激活与心衰风险:IVW法OR .508(95%CI .343–.754),MR-RAPS法OR .499(95%CI .327–.762)。

临床怎么用

  • 支持在非肥胖、非糖尿病的射血分数保留型心衰患者中开展GLP-1受体激动剂相关临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists reduce heart failure (HF) risk in patients with diabetes or obesity. However, the extent to which this reduced risk is dependent on, or extends beyond, glucose control and weight reduction remains unclear. METHODS: Two-sample cis-Mendelian randomization (MR) was used to assess causal effects of GLP-1R activation on HF risk, using glycated haemoglobin (HbA1c) reduction as a surrogate biomarker. The HF outcome was derived from a genome-wide association meta-analysis that included seven original studies and 1 665 481 participants. Primary analyses used inverse variance-weighted (IVW) and MR-robust adjusted profile score (MR-RAPS) methods. Mendelian randomization Bayesian model averaging was used to identify key mediators of the observed effects, while multivariable cis-MR with principal component generalized method of moments and network cis-MR were used to minimize the impact of confounders. RESULTS: Genetically proxied GLP-1R activation was associated with reduced HF risk {IVW: odds ratio [OR] [95% confidence interval (CI)] .502 [.339, .743]; MR-RAPS: OR [95% CI] .492 [.320, .756]}. Mendelian randomization Bayesian model averaging identified body mass index (BMI) (marginal inclusion probability 67.2%) and Type 2 diabetes (T2D) (45.0%) as primary mediators. In multivariable cis-MR with principal component generalized method of moments, genetically predicted HbA1c levels from the GLP-1R locus remained significantly associated with HF risk after BMI adjustment, even in instances where BMI effects were non-significant [OR (95% CI) 1.663 (1.087, 2.544) at 99% variance threshold]. Network cis-MR confirmed persistent protection after adjusting for BMI [IVW: OR (95% CI) .587 (.394, .877); MR-RAPS: OR (95% CI) .577 (.375, .887)] or T2D [IVW: OR (95% CI) .508 (.343, .754); MR-RAPS: OR (95% CI) .499 (.327, .762)]. CONCLUSIONS: Glucagon-like peptide-1 receptor agonist-associated HF risk reduction is primarily mediated by BMI reduction rather than glucose control, but not fully explained by either. Residual effects after BMI and T2D adjustment suggest direct cardioprotective actions, supporting trials in non-obese, non-diabetic HF patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hu, Zhao, Dai, et al. GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. Eur Heart J. 2026. PMID: 41609518. doi:10.1093/eurheartj/ehaf1066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。